Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dermata Therapeutics Inc (NQ: DRMA )

0.3320 -0.0248 (-6.95%)
Streaming Delayed Price Updated: 10:48 AM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Dermata Therapeutics Inc

< Previous 1 2 Next >
Dermata to Present at the Emerging Growth Conference on April 3, 2024
Via ACCESSWIRE
Dermata to Present at the Emerging Growth Conference on February 7, 2024
Via ACCESSWIRE
Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis
Via ACCESSWIRE
Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
Via ACCESSWIRE
Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols
Via ACCESSWIRE
Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Via ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Via ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Via ACCESSWIRE
Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Via ACCESSWIRE
Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne
Via ACCESSWIRE
Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
Via ACCESSWIRE
Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results
Via ACCESSWIRE
Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
Via ACCESSWIRE
Dermata Therapeutics Inc. (NASDAQ: DRMA) Highlighted for Surprising Price Action
Via Investor Brand Network
Dermata Therapeutics Inc. (NASDAQ: DRMA) Near Top of Volume Charts in Friday Trading
Via Investor Brand Network
Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package
Via ACCESSWIRE
Dermata Therapeutics Inc. (NASDAQ: DRMA) is One of Friday Morning’s Most Active Stocks
Via Investor Brand Network
Dermata Therapeutics Announces Closing of $5.0 Million Public Offering
Via ACCESSWIRE
Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering
Via ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results
Via ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Via ACCESSWIRE
Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea
Via ACCESSWIRE
Dermata to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Via ACCESSWIRE
Dermata to Participate in the Gilmartin Group Emerging Growth Company Showcase
Via ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Via ACCESSWIRE
Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe Rosacea
- Topline results expected in the second half of 2022 - 
From Dermata Therapeutics
Via AccessWire
Dermata to Present at the H.C. Wainwright Global Investment Conference
SAN DIEGO, CA / ACCESSWIRE / May 23, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and... 
From Dermata Therapeutics
Via AccessWire
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
Dermata completes a $5.0 million private placement financing DMT310 Phase 2 rosacea trial topline results expected in H2 2022 SAN DIEGO, CA / ACCESSWIRE / May 16, 2022 / Dermata Therapeutics, Inc.... 
From Dermata Therapeutics
Via AccessWire
Exposures Product Safety
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.